Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A media release issued earlier today by Barvarian Nordic (the developer of Prostvac®) gives us an inkling of where we may be headed in the development of combination therapies for the management of late stage (and maybe even earlier stage) forms of prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castrate-resistant, combination, immunotherapeutic, ipilimumab, mCRPC, outcome, Prostvac, survival | Leave a Comment »
The US Food & Drug Administration (FDA) has advised GTx to stop development of GTx-758 (also known as Capesaris), its oral drug intended for the treatment of men with advanced prostate cancer, after it became apparent that there was an increase in risk for blood clots in men taking active drug compared to those being [...]
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: blood clots, Capesaris, complications, GTx-758, risk | Leave a Comment »
According to a recently published research letter, men with prostate cancer who live close to the Loma Linda proton beam radiation therapy (PBRT) center are five times more likely to choose PBRT for their treatment than are other men who live in California but don’t live close to Loma Linda! DUH!
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Loma Linda, PBRT, proton beam | 2 Comments »
A new study has attempted to calculate the impact of age, health status, and patient preference on the relative outcomes (and merits) of immediate surgery as compared to active surveillance for the management of low-risk prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, life, low, outcome, quality, risk, surgery | 3 Comments »
A new study on relative rates of survival at 10 years, just published on line, is probably going to get differing reactions from patients and from physicians depending on their individual points of view.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: comparative, mortality, outcome, survival | 7 Comments »
We are having a hard time with a media release issued yesterday by BJU International in relation to a study just published in that journal by Tewari et al. (Actually, we are having a hard time with the results of the study itself too.)
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: age, follow-up, orgasm, potency, RALP, sexual function | 4 Comments »
An article just published by Grimm et al. in a supplement to BJU International argues (quite persuasively) that low-dose brachytherapy is the best form of treatment for men with low-risk prostate cancer.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: brachytherapy, comparative, low risk, low-dose, outcome | 1 Comment »
The American Society for Clinical Oncology (ASCO) has just released a formal “provisional clinical opinion” on the integration of palliative care into standard care for patients with cancer. The full text of this article is available on line.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: care, curative, oncologic, palliative | 1 Comment »
A new paper in this month’s Journal of Urology has attempted to document the potential number of years of life lost (PYLL) to prostate cancer (and other forms of urogenital cancer) between 1972 and 2006 — based on the Surveillance, Epidemiology and End Results (SEER) data.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: life, lost, PYLL, years | 5 Comments »
A new report just published on line in the Journal of Urology has shown that — at least in the state of North Carolina — distance from the nearest urologist affects prostate cancer risk category at diagnosis and may disproportionately impact black as opposed to white patients.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: category, distance, race, risk, urologist | 1 Comment »
A new paper by clinical researchers in Korea has concluded that treatment with high-intensity focused ultrasound (HIFU) “does not provide effective oncologic outcomes even in low risk patients with prostate cancer as well as in the intermediate or high risk groups,” but does have a low associated incidence of treatment complications.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: complications, first line, HIFU, high-intensity focused ultrasound, outcome | 2 Comments »
Has the clinical success of some new drugs started to affect enrollment in trials of others for advanced forms of prostate cancer?
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ipilimumab, TAK-700, tasquinimod, trials | Leave a Comment »
A study just published on line in Cancer Epidemiology, Biomarkers & Prevention has suggested (albeit not for the first time) that a baseline history of coronary artery disease may be a meaningful risk factor for prostate cancer.
Filed under: Diagnosis, Management, Risk | Tagged: coronary artery disease, heart disease, risk | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site